- Molecular NameEletriptan
- Synonymeletriptan
- Weight382.528
- Drugbank_IDDB00216
- ACS_NO143322-58-1
- Show 2D model
- LogP (experiment)3.587
- LogP (predicted, AB/LogP v2.0)3.78
- pkaN/A
- LogD (pH=7, predicted)1.66
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.36
- LogSw (predicted, AB/LogsW2.0)0.02
- Sw (mg/ml) (predicted, ACD/Labs)0.07
- No.of HBond Donors1
- No.of HBond Acceptors4
- No.of Rotatable Bonds6
- TPSA61.55
- StatusFDA approved
- AdministrationN/A
- PharmacologyA second generation triptan drug marketed and manufactured by Pfizer Inc for the treatment of migraine headaches.
- Absorption_valueN/A
- Absorption (description)Well absorbed after oral administration with a mean absolute bioavailability of approximately 50%.
- Caco_2N/A
- Bioavailability50.0
- Protein binding88.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIn vitro studies indicate that eletriptan is primarily metabolized by cytochrome P-450 enzyme CYP3A4. The N-demethylated metabolite of eletriptan is the only known active metabolite.
- Half life4 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityBased on the pharmacology of the 5-HT1B/1D agonists, hypertension or other more serious cardiovascular symptoms could occur on overdose.
- LD50 (rat)N/A
- LD50 (mouse)N/A